SHANGHAI JUNSHI BIO YC1 Total Liabilities
SHANGHAI JUNSHI BIO YC1 total liabilities. Based on the latest financial reports, SHANGHAI JUNSHI BIO YC1 (8SJ) has total liabilities worth €6.33 Billion EUR (≈ $7.40 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of SHANGHAI JUNSHI BIO YC1 to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SHANGHAI JUNSHI BIO YC1 (2021–2025)
Total liabilities of SHANGHAI JUNSHI BIO YC1 from 2021 to 2025. This chart illustrates how SHANGHAI JUNSHI BIO YC1's total liabilities have evolved over time, based on quarterly financial data.
SHANGHAI JUNSHI BIO YC1 Competitors by Total Liabilities
The table below lists competitors of SHANGHAI JUNSHI BIO YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yunnan Yunwei Co Ltd Class A
SHG:600725
|
China | CN¥96.71 Million |
|
Zhuhai Huajin Capital Co Ltd
SHE:000532
|
China | CN¥772.99 Million |
|
Suzhou Sunmun Technology Co Ltd
SHE:300522
|
China | CN¥347.54 Million |
|
GEOPARK LTD. DL -001
F:G6O
|
Germany | €794.65 Million |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
China | CN¥6.72 Billion |
|
Laurent-Perrier
PA:LPE
|
France | €491.23 Million |
|
Vatti Corp Ltd
SHE:002035
|
China | CN¥2.89 Billion |
|
Loctek Ergonomic Technology Corp Class A
SHE:300729
|
China | CN¥5.87 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SHANGHAI JUNSHI BIO YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SHANGHAI JUNSHI BIO YC1 assets under control.
Liquidity & Leverage Metrics
SHANGHAI JUNSHI BIO YC1 Total Liabilities Ratios Explained
SHANGHAI JUNSHI BIO YC1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SHANGHAI JUNSHI BIO YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SHANGHAI JUNSHI BIO YC1 (2021–2025)
The table below shows the annual total liabilities of SHANGHAI JUNSHI BIO YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €6.33 Billion ≈ $7.40 Billion |
+30.43% |
| 2024-12-31 | €4.85 Billion ≈ $5.67 Billion |
+20.57% |
| 2023-12-31 | €4.02 Billion ≈ $4.70 Billion |
+44.58% |
| 2022-12-31 | €2.78 Billion ≈ $3.25 Billion |
+2.34% |
| 2021-12-31 | €2.72 Billion ≈ $3.18 Billion |
-- |
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more